Supercritical CO2 Antisolvent-Micronised Naringin and Naringenin Alleviate Paclitaxel-Induced Pain Syndrome
Pharmaceutics · 17.06.2026 · 18 (6) · 747
DOI: 10.3390/pharmaceutics18060747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 17.06.2026. Verfasst von Gabriela Adriany Lisboa Zilli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Environmental Sciences, Community University of Chapecó Region-Unochapecó, Chapecó 89809-900, SC, Brazil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina, Coordenação de Aperfeicoamento de Pessoal de Nível Superior, National Council for Scientific and Technological Development.
Abstract (Originalsprache)
Background/Objectives: Paclitaxel is a chemotherapy drug used to treat various tumours, but its use is often limited by an acute and chronic pain syndrome that is poorly managed. Naringin and its aglycone, naringenin, exhibit antioxidant, antitumour, anti-inflammatory, and antinociceptive effects, making them potential alternative treatments. However, their low water solubility limits their oral bioavailability in humans. Micronisation in a supercritical medium reduces particle size and enhances the dissolution of compounds, offering a possible solution. In this study, we investigated whether micronising naringin and naringenin via supercritical technology could improve their dissolution and oral efficacy against paclitaxel-induced pain syndrome.
Methods
Micronisation was performed using supercritical CO2. Molecular docking was used to analyse the binding of naringin and naringenin to TRPV1, a key target for pain relief. Swiss mice were used in capsaicin (TRPV1 agonist)-induced nociception and paclitaxel-caused acute and chronic pain models. We assessed mechanical, cold, and heat sensitivity, potential adverse effects, and TRPV1 mRNA expression.
Results
Micronisation improved the apparent dissolution profile of molecules. Docking results showed that naringin and naringenin bind to TRPV1. Both micronised compounds reduced capsaicin-induced nociception without affecting locomotion or body temperature. Micronised naringin and naringenin alleviated mechanical and cold allodynia, as well as thermal hyperalgesia in both acute and chronic paclitaxel-induced pain, outperforming their conventional forms. They also downregulated TRPV1 mRNA expression in the mice’s sciatic nerve.
Conclusions
Taken together, these results show that supercritical micronisation improved the apparent dissolution and oral antinociceptive efficacy of naringin and naringenin, emphasising their potential as promising alternatives for managing paclitaxel-induced pain, with TRPV1 being a probable contributor to the observed antinociceptive effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate Program in Environmental Sciences, Community University of Chapecó Region-Unochapecó, Chapecó 89809-900, SC, Brazil.
- Behavioural and Neurochemistry Pharmacology of Pain Research Group, Community University of Chapecó Region-Unochapecó, Chapecó 89809-900, SC, Brazil.
- Department of Chemical and Food Engineering, Federal University of Santa Catarina-UFSC, Florianópolis 88040-900, SC, Brazil.
- Graduate Program in Biological Sciences: Toxicological Biochemistry, Centre of Natural and Exact Sciences, Federal University of Santa Maria-UFSM, Santa Maria 97105-900, RS, Brazil.
ORCID-Profile: Samara Cristina Mazon, Felipe Zaniol, Ana Lúcia Anversa Segatto
Förderung
- Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- National Council for Scientific and Technological Development
- Fundação de Amparo à Pesquisa do Estado de Santa Catarina—Brazil
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico—Brazil
Zitieren
APA
Zilli, G. A. L., Mazon, S. C., Oliveira, P. V., Zaniol, F., Barros, E. L. D. S., Lodi, Â. M., Saretto, C. L., Cardoso, H., Segatto, A. L. A., Oliveira, S. M., Oliveira, J. V., & Brusco, I. (2026). Supercritical CO2 Antisolvent-Micronised Naringin and Naringenin Alleviate Paclitaxel-Induced Pain Syndrome. Pharmaceutics, 18(6), 747. https://doi.org/10.3390/pharmaceutics18060747
Vancouver
Zilli GAL, Mazon SC, Oliveira PV, Zaniol F, Barros ELDS, Lodi ÂM, et al. Supercritical CO2 Antisolvent-Micronised Naringin and Naringenin Alleviate Paclitaxel-Induced Pain Syndrome. Pharmaceutics. 2026;18(6):747. doi:10.3390/pharmaceutics18060747
BibTeX
@article{Zilli2026,
author = {Zilli, Gabriela Adriany Lisboa and Mazon, Samara Cristina and Oliveira, Patricia Viera de and Zaniol, Felipe and Barros, Eulália Lopes da Silva and Lodi, Ângela Maria and Saretto, Chaiane Lunelli and Cardoso, Hemyly and Segatto, Ana Lúcia Anversa and Oliveira, Sara Marchesan and Oliveira, J Vladimir and Brusco, Indiara},
title = {Supercritical CO2 Antisolvent-Micronised Naringin and Naringenin Alleviate Paclitaxel-Induced Pain Syndrome},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {6},
pages = {747},
doi = {10.3390/pharmaceutics18060747}
}
EUVIMED